Business, energy, technology, markets and global industry news from Business News Today

LITESPARK-022

PharmaDeviceNews LITESPARK-022
Representative image of a clinician reviewing kidney cancer scans, reflecting Merck & Co., Inc.’s FDA approval of Keytruda and Welireg combinations for adjuvant clear cell renal cell carcinoma treatment.
Pharma & Biotech

Merck moves Welireg earlier as FDA clears Keytruda combinations in high-risk ccRCC

Find out how Merck’s Keytruda and Welireg approval could reshape adjuvant clear cell renal cell carcinoma treatment.

Read More
KEYTRUDA and WELIREG deliver Phase 3 LITESPARK-022 win in adjuvant clear cell renal cell carcinoma, reshaping post-nephrectomy care
Pharma & Biotech

Merck’s KEYTRUDA plus WELIREG cuts recurrence risk in Phase 3 LITESPARK-022 trial for adjuvant clear cell renal cell carcinoma

KEYTRUDA plus belzutifan cuts recurrence risk in adjuvant RCC. Explore what LITESPARK-022 changes for kidney cancer treatment.

Read More